Profile data is unavailable for this security.
About the company
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
- Revenue in USD (TTM)642.27m
- Net income in USD-177.65m
- Incorporated2000
- Employees1.49k
- LocationNovocure LtdNo. 4 The Forum, Grenville StreetSAINT HELIER JE2 4UFJerseyJEY
- Phone+44 1 534756700
- Websitehttps://www.novocure.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Integra Lifesciences Holdings Corp | 1.64bn | -495.34m | 881.74m | 4.40k | -- | 0.8492 | -- | 0.5367 | -6.46 | -6.46 | 21.45 | 13.33 | 0.4261 | 1.52 | 6.34 | 373,741.10 | -12.85 | 2.90 | -15.39 | 3.25 | 57.21 | 62.59 | -30.15 | 7.14 | 1.80 | 2.68 | 0.6383 | 0.00 | 4.47 | 1.20 | -110.25 | -- | -3.19 | -- |
| Inmode Ltd | 370.50m | 93.83m | 906.03m | 660.00 | 9.91 | 1.33 | 9.58 | 2.45 | 1.44 | 1.44 | 5.67 | 10.78 | 0.4774 | 1.19 | 9.28 | 561,356.10 | 12.09 | 24.21 | 13.30 | 26.82 | 78.54 | 82.36 | 25.33 | 38.64 | 8.83 | -- | 0.00 | 0.00 | -6.16 | 12.44 | -48.24 | 4.57 | 15.99 | -- |
| Castle Biosciences Inc | 343.53m | -12.24m | 967.60m | 761.00 | -- | 2.07 | 31.70 | 2.82 | -0.4533 | -0.4533 | 11.67 | 16.02 | 0.6377 | 9.05 | 6.89 | 451,419.20 | -2.27 | -6.95 | -2.50 | -7.52 | 79.94 | 80.76 | -3.56 | -17.49 | 6.31 | -- | 0.0218 | -- | 51.09 | 44.97 | 131.75 | 43.57 | 97.74 | -- |
| BioLife Solutions Inc | 88.83m | -13.99m | 1.07bn | 159.00 | -- | 3.01 | -- | 12.05 | -0.2922 | -0.061 | 1.87 | 7.37 | 0.2296 | 0.8875 | 6.18 | 558,698.10 | -3.62 | -1.92 | -3.92 | -2.10 | 70.02 | 52.54 | -15.75 | -9.06 | 3.64 | -- | 0.0207 | -- | 8.44 | 24.62 | 38.27 | -- | 19.15 | -- |
| Novocure Ltd | 642.27m | -177.65m | 1.23bn | 1.49k | -- | 3.61 | -- | 1.92 | -1.61 | -1.61 | 5.81 | 3.05 | 0.4973 | 4.01 | 8.43 | 431,632.40 | -13.75 | -9.61 | -33.14 | -11.84 | 75.57 | 77.57 | -27.66 | -19.32 | 1.50 | -- | 0.6887 | -- | 18.82 | 11.49 | 18.55 | -- | 32.52 | -- |
| Enovis Corp | 2.23bn | -1.37bn | 1.25bn | 7.37k | -- | 0.6161 | -- | 0.5575 | -24.20 | -24.20 | 39.35 | 35.33 | 0.4474 | 1.56 | 5.37 | 303,144.60 | -27.38 | -3.14 | -30.81 | -3.56 | 57.19 | 52.01 | -61.19 | -9.77 | 1.16 | 0.0495 | 0.4018 | -- | 23.46 | -8.73 | -1,423.10 | -- | 7.58 | -- |
| Iradimed Corp | 83.81m | 22.48m | 1.27bn | 160.00 | 57.06 | 13.42 | 75.47 | 15.15 | 1.75 | 1.75 | 6.52 | 7.44 | 0.8094 | -- | -- | -- | 21.71 | 18.06 | 23.86 | 20.21 | 76.75 | 76.85 | 26.82 | 25.51 | -- | -- | -- | -- | 14.43 | 21.45 | 16.88 | 108.61 | -- | -- |
| Tandem Diabetes Care Inc | 1.01bn | -203.37m | 1.28bn | 2.65k | -- | 9.66 | -- | 1.28 | -3.05 | -3.05 | 15.08 | 1.96 | 1.10 | 3.25 | 8.64 | 380,000.40 | -22.20 | -10.11 | -30.80 | -12.33 | 53.23 | 51.67 | -20.20 | -11.71 | 1.90 | -9.88 | 0.7028 | -- | 25.74 | 21.01 | 56.86 | -- | 27.42 | -- |
| Conmed Corp | 1.37bn | 47.06m | 1.29bn | 3.90k | 27.59 | -- | 10.67 | 0.9416 | 1.52 | 1.52 | 44.24 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 54.08 | 55.56 | 3.42 | 3.78 | -- | 3.24 | -- | -- | 5.18 | 9.77 | -64.47 | 37.66 | -- | -5.59 |
| Adapthealth Corp | 3.26bn | 75.81m | 1.38bn | 10.50k | 18.37 | 0.8544 | 2.90 | 0.4243 | 0.5553 | 0.5553 | 23.90 | 11.94 | 0.7354 | 17.20 | 8.33 | 310,020.30 | 1.96 | -2.81 | 2.28 | -3.17 | 25.32 | 19.63 | 2.67 | -4.19 | 0.8584 | 2.30 | 0.5253 | -- | 1.90 | 43.84 | 112.19 | -- | 70.36 | -- |
| Procept Biorobotics Corp | 299.91m | -84.58m | 1.55bn | 756.00 | -- | 4.08 | -- | 5.18 | -1.54 | -1.54 | 5.45 | 6.81 | 0.6772 | 1.81 | 3.91 | 396,702.40 | -19.10 | -26.94 | -21.74 | -29.81 | 64.55 | 54.37 | -28.20 | -83.14 | 7.20 | -- | 0.1194 | -- | 64.84 | 105.21 | 13.68 | -- | -10.34 | -- |
| Pulse Biosciences Inc | 86.00k | -74.73m | 1.56bn | 75.00 | -- | 16.82 | -- | 18,131.77 | -1.14 | -1.14 | 0.0013 | 1.37 | 0.0009 | -- | -- | 1,146.67 | -74.06 | -83.75 | -80.63 | -94.40 | -224.42 | -- | -86,898.84 | -12,644.52 | 10.01 | -- | 0.00 | -- | -- | -- | -26.95 | -- | -27.12 | -- |
| Kestra Medical Technologies Ltd | 74.26m | -138.79m | 1.57bn | 330.00 | -- | 8.44 | -- | 21.15 | -2.76 | -2.76 | 1.47 | 3.19 | 0.4034 | -- | 9.40 | 225,027.30 | -71.43 | -122.23 | -92.37 | -192.35 | 46.40 | -- | -177.06 | -342.51 | -- | -116.72 | 0.2033 | -- | 115.05 | -- | -25.08 | -- | 150.61 | -- |
| Quidelortho Corp | 2.73bn | -1.13bn | 1.60bn | 6.60k | -- | 0.8341 | -- | 0.5867 | -16.66 | -16.66 | 40.27 | 28.27 | 0.4478 | 2.62 | 7.46 | -- | -18.56 | -6.45 | -22.13 | -7.39 | 46.67 | 53.89 | -41.45 | -14.40 | 0.9002 | 0.6757 | 0.5798 | -- | -1.89 | 10.44 | 44.84 | -- | -- | -- |
| AtriCure Inc | 518.31m | -28.77m | 1.62bn | 1.30k | -- | 3.41 | -- | 3.13 | -0.608 | -0.608 | 10.90 | 9.59 | 0.829 | 1.68 | 8.79 | 398,696.20 | -4.60 | -3.84 | -5.24 | -4.25 | 74.87 | 74.53 | -5.55 | -7.13 | 2.85 | -17.96 | 0.1252 | -- | 16.55 | 15.05 | -46.85 | -- | 14.00 | -- |
Data as of Feb 13 2026. Currency figures normalised to Novocure Ltd's reporting currency: US Dollar USD
53.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 16.77m | 15.04% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 10.10m | 9.06% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 9.02m | 8.09% |
| Soleus Capital Management LP (Investment Management)as of 31 Dec 2025 | 8.53m | 7.65% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 4.97m | 4.46% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 2.58m | 2.31% |
| Geode Capital Management LLCas of 31 Dec 2025 | 2.48m | 2.22% |
| BlackRock Advisors LLCas of 31 Dec 2025 | 1.88m | 1.69% |
| Quantinno Capital Management LPas of 30 Sep 2025 | 1.52m | 1.37% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 1.39m | 1.25% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
